Home

Download

Statistics

Landscape

Help

Contact

	Dataset summary
	Drug summary
	Umap of single cell types and conditions (resistant and sensitive)
	Comparison of cell composition between the resistant and sensitive groups (This dataset does not contain this module)
	Comparison of intra-tumor heterogeneity (ITH) and epithelial-mesenchymal transition (EMT) scores of malignant cells between the resistant and sensitive groups
	Difference of cell-cell interactions between the resistant and sensitive groups
	Differentially expressed genes (DEGs) between the resistant and sensitive groups for each cell type
	Mechanism analysis of drug resistance-related DEGs for each cell type in the pre-treatment samples (This dataset does not contain this module)
	Mechanism analysis of drug resistance-related DEGs for each cell type in the post-treatment samples
	Mechanism analysis of drug resistance-related DEGs for each cell type in one patient or cell lines (This dataset does not contain this module)
	MicroRNAs (miRNAs) regulating drug resistance-related DEGs for Malignant cells
	Motifs and transcription factors (TFs) regulating drug resistance-related DEGs for each cell type
•	Differentially expressed genes act as transcription factors

Dataset: GSE207422_Tor

Dataset summary for GSE207422_Tor

Datast information	Dataset	GSE207422_Tor
	PMID	36869384
	Raw data ID/link	https://ngdc.cncb.ac.cn/gsa-human/browse/HRA001033
	Organism	Homo sapiens
	Source	patients
	Tissue	Tumor tissue
	Cancer type level1	Lung cancer
	Cancer type level2	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)
	Regimen	toripalimab + carboplatin + (docetaxel or pemetrexed or emcitabine)
	Drug type	Immunotherapy
	Sample size	post (resistant 3, sensitive 2)
	Cell number	8690
	Extract protocol	BD Rhapsody system
	Data processing	BD Rhapsody Whole Transcriptome Analysis (WTA) Pipeline
	Public date	Public on Mar 21, 2023
	Description	This dataset has 5 patients with post-treatment samples.

Top

Drug summary for GSE207422_Tor

Drug name	DrugBank ID	Drug type	Targets name	Targets uniprot ID
"Toripalimab"	DB15043	biotech	PDCD1	Q15116
"carboplatin" is not included in the drug list.
"Docetaxel"	DB01248	small molecule	TUBB1; MAP2; MAP4; MAPT; BCL2; NR1I2	Q9H4B7; P11137; P27816; P10636; P10415; O75469
"Pemetrexed"	DB00642	small molecule	TYMS; ATIC; DHFR; GART	P04818; P31939; P00374; P22102
"emcitabine" is not included in the drug list.

Top

Umap of single cell types and conditions (resistant and sensitive)

Umap of cell types and conditions (resistant and sensitive). If this dataset has both pre-treatment and post-treatment samples, the cell types were annotated together. If this dataset is a cell line dataset, the UMAP of cell clusters and the cell ratio of drug-resistant and sensitive groups within each cluster will also be shown. (If the image exists, the user can click on it to enlarge it in a new window.)

Umap of cell types

Umap of conditions

Top

Comparison of cell composition between the resistant and sensitive groups

In the pre-treatment samples, the cell composition of the resistant and sensitive groups were compared.
* represents significant difference. (If the image exists, the user can click on it to enlarge it in a new window.)

In the post-treatment samples, the cell composition of the resistant and sensitive groups were compared.
* represents significant difference. (If the image exists, the user can click on it to enlarge it in a new window.)

Top

Comparison of ITH and EMT scores of malignant cells between the resistant and sensitive groups

Comparison of ITH (intra-tumoral heterogeneity) and EMT (epithelial-mesenchymal transition) scores of malignant cells between the resistant and sensitive groups. ITH represents intratumoral heterogeneity, EMT represents epithelial mesenchymal transition, pre represents pre-treatment, post represents post-treatment, post2 represents longer post-treatment. (If the image exists, the user can click on it to enlarge it in a new window.)

Comparison of ITH scores

Comparison of EMT scores

Top

Difference of cell-cell interactions between the resistant and sensitive groups

In the pre-treatment samples, the difference in cell-cell interactions between the resistant and sensitive groups was compared. The numbers indicate the count of cell-cell interactions that were either higher or lower in the resistant group compared to the sensitive group. The dot plots of significant ligand-receptor pairs in the resistant group and sensitive group are subsequently displayed. (If the image exists, the user can click on it to enlarge it in a new window. Complete files can be downloaded from the download section.)

In the post-treatment samples, the difference in cell-cell interactions between the resistant and sensitive groups was compared. The numbers indicate the count of cell-cell interactions that were either higher or lower in the resistant group compared to the sensitive group. The dot plots of significant ligand-receptor pairs in the resistant group and sensitive group are subsequently displayed. (If the image exists, the user can click on it to enlarge it in a new window. Complete files can be downloaded from the download section.)

resistant vs. sensitive

Dot plot of significant ligand-receptor pairs in the resistant group	Dot plot of significant ligand-receptor pairs in the sensitive group

This dataset only has one patient or is a cell line dataset, the resistant sample is the post-treatment sample and the sensitive sample is the pre-treatment sample. The difference in cell-cell interactions between the resistant and sensitive groups was compared. The numbers indicate the count of cell-cell interactions that were either higher or lower in the resistant group compared to the sensitive group. The dot plots of significant ligand-receptor pairs in the resistant group and sensitive group are subsequently displayed. (If the image exists, the user can click on it to enlarge it in a new window. Complete files can be downloaded from the download section.)

Top

Differentially expressed genes (DEGs) between the resistant and sensitive groups for each cell type

In the pre-treatment samples, the differentially expressed genes (|avg_log2FC|>0.25 & p_val_adj<0.05) between the resistant and sensitive groups for each cell type.

In the post-treatment samples, the differentially expressed genes (|avg_log2FC|>0.25 & p_val_adj<0.05) between the resistant and sensitive groups for each cell type.

Gene symbol	Gene id	avg_log2FC	p_val	p_val_adj	pct.1	pct.2	Cell type	Timepoint
SERP1	ENSG00000120742	0.502223	1.71e-32	3.83e-28	0.709	0.356	Malignant cells	post
UBE2H	ENSG00000186591	0.501134	6.81e-27	1.53e-22	0.537	0.226	Malignant cells	post
STEAP4	ENSG00000127954	0.500771	2.80e-24	6.28e-20	0.307	0.055	Malignant cells	post
ELF3	ENSG00000163435	0.500406	1.24e-19	2.79e-15	0.592	0.338	Malignant cells	post
CDK2AP2	ENSG00000167797	0.499991	3.28e-30	7.36e-26	0.396	0.088	Malignant cells	post
HMGN1	ENSG00000205581	0.498031	1.66e-30	3.73e-26	0.726	0.424	Malignant cells	post
PPP1R1B	ENSG00000131771	0.497328	1.76e-26	3.95e-22	0.266	0.024	Malignant cells	post
ODC1	ENSG00000115758	0.496137	4.50e-23	1.01e-18	0.429	0.149	Malignant cells	post
PRDX5	ENSG00000126432	0.494781	3.03e-25	6.81e-21	0.659	0.349	Malignant cells	post
ANXA2	ENSG00000182718	0.493157	9.61e-13	2.16e-08	0.945	0.936	Malignant cells	post
SDR16C5	ENSG00000170786	0.492849	4.63e-31	1.04e-26	0.361	0.057	Malignant cells	post
GALNT1	ENSG00000141429	0.491093	4.38e-16	9.83e-12	0.444	0.22	Malignant cells	post
NFKBIA	ENSG00000100906	0.49055	4.60e-09	1.03e-04	0.512	0.382	Malignant cells	post
PHLDA1	ENSG00000139289	0.49009	8.39e-27	1.89e-22	0.252	0.015	Malignant cells	post
TFPI	ENSG00000003436	0.488394	7.22e-15	1.62e-10	0.303	0.112	Malignant cells	post
PPIB	ENSG00000166794	0.485344	2.45e-36	5.50e-32	0.45	0.09	Malignant cells	post
RPS26	ENSG00000197728	0.481617	1.57e-14	3.52e-10	0.537	0.312	Malignant cells	post
NEDD9	ENSG00000111859	0.481036	4.51e-24	1.01e-19	0.326	0.07	Malignant cells	post
MT-RNR2	ENSG00000210082	0.47872	8.09e-27	1.82e-22	0.994	0.976	Malignant cells	post
RAB11A	ENSG00000103769	0.477449	1.82e-32	4.08e-28	0.514	0.165	Malignant cells	post
ITGB6	ENSG00000115221	0.474088	2.68e-27	6.03e-23	0.374	0.079	Malignant cells	post
HERPUD1	ENSG00000051108	0.472154	8.29e-31	1.86e-26	0.397	0.081	Malignant cells	post
CYP4B1	ENSG00000142973	0.47121	1.19e-23	2.68e-19	0.255	0.029	Malignant cells	post
TMBIM6	ENSG00000139644	0.468071	4.54e-35	1.02e-30	0.913	0.677	Malignant cells	post
CYSTM1	ENSG00000120306	0.463322	3.78e-26	8.48e-22	0.483	0.171	Malignant cells	post
UBC	ENSG00000150991	0.461894	7.59e-24	1.70e-19	0.771	0.527	Malignant cells	post
AHCYL2	ENSG00000158467	0.461632	9.94e-28	2.23e-23	0.339	0.062	Malignant cells	post
MEGF9	ENSG00000106780	0.452954	1.71e-24	3.83e-20	0.364	0.097	Malignant cells	post
RBPMS	ENSG00000157110	0.45102	1.96e-23	4.40e-19	0.387	0.116	Malignant cells	post
HPCAL1	ENSG00000115756	0.44797	3.94e-31	8.84e-27	0.344	0.048	Malignant cells	post
CD47	ENSG00000196776	0.447239	1.55e-21	3.48e-17	0.473	0.2	Malignant cells	post
TMEM106B	ENSG00000106460	0.447216	2.34e-26	5.26e-22	0.403	0.116	Malignant cells	post
EIF2S2	ENSG00000125977	0.446082	2.26e-07	5.08e-03	0.643	0.607	Malignant cells	post
ARL6IP5	ENSG00000144746	0.44516	2.96e-27	6.64e-23	0.39	0.092	Malignant cells	post
SSBP1	ENSG00000262771	0.444695	2.76e-26	6.20e-22	0.578	0.268	Malignant cells	post
PNRC1	ENSG00000146278	0.444551	2.06e-18	4.63e-14	0.325	0.105	Malignant cells	post
MYO6	ENSG00000196586	0.443785	1.72e-24	3.86e-20	0.448	0.163	Malignant cells	post
TMED9	ENSG00000184840	0.442372	9.14e-28	2.05e-23	0.514	0.193	Malignant cells	post
TMEM59	ENSG00000116209	0.442016	3.35e-25	7.52e-21	0.453	0.152	Malignant cells	post
SBDS	ENSG00000126524	0.441924	9.56e-27	2.15e-22	0.507	0.193	Malignant cells	post
TNFSF10	ENSG00000121858	0.440999	9.54e-18	2.14e-13	0.397	0.158	Malignant cells	post
H3F3B	NA	0.440549	3.96e-21	8.91e-17	0.92	0.842	Malignant cells	post
ATP11A	ENSG00000068650	0.440141	8.80e-27	1.98e-22	0.293	0.04	Malignant cells	post
MICAL2	ENSG00000133816	0.439297	1.88e-23	4.22e-19	0.294	0.055	Malignant cells	post
CAPG	ENSG00000042493	0.437499	2.41e-29	5.41e-25	0.297	0.031	Malignant cells	post
SEC11C	ENSG00000166562	0.436711	4.70e-33	1.06e-28	0.357	0.048	Malignant cells	post
CKB	ENSG00000166165	0.435362	4.17e-25	9.38e-21	0.352	0.084	Malignant cells	post
BAG3	ENSG00000151929	0.43536	2.01e-20	4.52e-16	0.381	0.134	Malignant cells	post
NOP10	ENSG00000182117	0.433374	9.33e-26	2.10e-21	0.486	0.18	Malignant cells	post
CAST	ENSG00000153113	0.432113	2.00e-26	4.50e-22	0.588	0.262	Malignant cells	post

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40

This dataset only has one patient or is a cell line dataset, the resistant sample is the post-treatment sample and the sensitive sample is the pre-treatment sample. The following are differentially expressed genes (|avg_log2FC|>0.25 & p_val_adj<0.05) between the resistant and sensitive groups for each cell type.

Top

Mechanism analysis of drug resistance-related DEGs for each cell type in the pre-treatment samples

Enrichment results for 5 known drug-resistant mechanisms in malignant cells and 1 known mechanism in TME cells.The "Signature" column represents the differentially expressed genes (DEGs) used for enrichment. The "Geneset" column represents the genes included in this mechanism. The "Overlap" column represents the number of genes in the "Geneset" that are enriched in the "Signature". The "Enriched Genes" column represents the genes in the "Geneset" that are enriched in the "Signature". (If the image exists, the user can click on it to enlarge it in a new window.)

Hallmark, KEGG and GOBP enrichment results for up-regulated genes in resistant group of pre-treatment samples. Only show the top 50 pathways with fdr<0.05. If certain cell types are not displayed, it means that there are no significant pathways based on DEGs in those cell types. (If the image exists, the user can click on it to enlarge it in a new window. Complete files can be downloaded from the download section.)

Hallmark, KEGG and GOBP enrichment results for down-regulated genes in resistant group of pre-treatment samples. Only show the top 50 pathways with fdr<0.05. If certain cell types are not displayed, it means that there are no significant pathways based on DEGs in those cell types. (If the image exists, the user can click on it to enlarge it in a new window.Complete files can be downloaded from the download section.)

Top

Mechanism analysis of drug resistance-related DEGs for each cell type in the post-treatment samples

Enrichment results for 5 known drug resistance mechanisms in malignant cells and 1 known mechanism in TME cells.The "Signature" column represents the differentially expressed genes (DEGs) used for enrichment. The "Geneset" column represents the genes included in this mechanism. The "Overlap" column represents the number of genes in the "Geneset" that are enriched in the "Signature". The "Enriched Genes" column represents the genes in the "Geneset" that are enriched in the "Signature". (If the image exists, the user can click on it to enlarge it in a new window.)

Enrichment results for 5 known drug resistance mechanisms in malignant cells

Mechnism	Pval	FDR	Signature	Geneset	Overlap	Background	Cell type	Enriched Genes
Unusual Activation of Pro-survival Pathway	1.00e-22	5.10e-22	945	781	96	23467	Malignant cells	PPP2R5A,ANXA2,AREG,BCL11A,CDKN1A,CERS2,DUSP6,EGFR,GSTP1,SLC2A1,HEY1,HSPA1A,IFI27,ISG15,JUN,PKM,MUC1,MYC,NFE2L2,RAB12,RHOA,RPS6,SOX2,TRIM16,YAP1,SLC25A5,AGR2,ANXA1,NET1,BAG3,HSPA5,ALCAM,CD44,CDKN2A,HSPD1,CLTC,CLU,CAPNS1,CTNND1,DDR1,DUSP1,EGR1,ERRFI1,EZR,FTL,GAPDH,GCLM,GCLC,GSR,HAX1,HBEGF,HSPA8,HK1,NFKBIA,ITGB1,ITGB8,TCF4,AK4,KLF4,LAMP2,LAMP3,LDHA,LRRFIP1,MTDH,NOTCH3,NQO1,NTRK2,TP63,PABPC1,PDCD10,PGK1,POMP,RAB27A,ERBB3,RND3,HNRNPA1,S100A11,TMED3,TMEM54,TNFSF10,TOP1,TUSC3,USP14,WNT5A,ENO1,SLC16A1,CALR,NPM1,CEBPD,DHCR24,GFPT1,INSIG1,BRD2,NKX2-1,FZD7,ALDH1A1
Irregularity in Drug Uptake and Drug Efflux	3.30e-03	8.40e-03	945	37	6	23467	Malignant cells	SLC2A1,ABCC1,ABCE1,ABCG1,ABCC5,SLC34A2
Drug Inactivation by Structure Modification	9.30e-02	1.60e-01	945	27	3	23467	Malignant cells	GSTP1,CES1,CMPK1
Aberration of the Drug's Therapeutic Target	3.00e-01	3.70e-01	945	90	5	23467	Malignant cells	EGFR,CDKN2A,NPM1,NECTIN4,LRRK2
Epigenetic Alteration of DNA, RNA or Protein	9.80e-01	9.80e-01	945	455	11	23467	Malignant cells	EGFR,H2AFY,LMNA,PMAIP1,CDKN2A,GAPDH,MALAT1,GDI2,PPP1R15A,MT-CO2,MX1

Enrichment results for 1 known drug resistance mechanisms in TME cells

Mechnism	Pval	FDR	Signature	Geneset	Overlap	Background	Cell type	Enriched Genes
Regulation by the Disease Microenvironment	2.90e-01	2.90e-01	239	186	3	23467	B cells	PAK1,CXCR4,MALAT1
Regulation by the Disease Microenvironment	1.80e-02	1.80e-02	126	186	4	23467	CD4+ T cells	CXCR4,JAK3,RHOB,VIM
Regulation by the Disease Microenvironment	6.20e-02	6.20e-02	114	186	3	23467	CD8+ T cells	CXCR4,RHOB,VIM
Regulation by the Disease Microenvironment	1.00e+00	1.00e+00	8	186	0	23467	Endothelial cells	NA
Regulation by the Disease Microenvironment	1.00e+00	1.00e+00	9	186	0	23467	Fibroblasts	NA
Regulation by the Disease Microenvironment	4.10e-02	4.10e-02	238	186	5	23467	Mono_Macro	VEGFA,CXCR4,IL1B,SOCS3,MALAT1
Regulation by the Disease Microenvironment	1.90e-02	1.90e-02	193	186	5	23467	Neutrophils	PTEN,IL1B,SOCS3,VIM,TIMP2
Regulation by the Disease Microenvironment	3.00e-01	3.00e-01	44	186	1	23467	pDCs	CXCR4
Regulation by the Disease Microenvironment	2.30e-02	2.30e-02	76	186	3	23467	Plasma cells	TP53INP1,CXCR4,VIM

Hallmark, KEGG and GOBP enrichment results for up-regulated genes in resistant group of post-treatment samples. Only show the top 50 pathways with fdr<0.05. If certain cell types are not displayed, it means that there are no significant pathways based on DEGs in those cell types. (If the image exists, the user can click on it to enlarge it in a new window. Complete files can be downloaded from the download section.)

Up-regulated Hallmark	Up-regulated KEGG	Up-regulated GO BP

Hallmark, KEGG and GOBP enrichment results for down-regulated genes in resistant group of post-treatment samples. Only show the top 50 pathways with fdr<0.05. If certain cell types are not displayed, it means that there are no significant pathways based on DEGs in those cell types. (If the image exists, the user can click on it to enlarge it in a new window. Complete files can be downloaded from the download section.)

Down-regulated Hallmark	Down-regulated KEGG	Down-regulated GO BP

Top

Mechanism analysis of drug resistance-related DEGs for each cell type in one patient or cell lines

This dataset only has one patient or is a cell line dataset, the resistant sample is the post-treatment sample and the sensitive sample is the pre-treatment sample. Enrichment results for 5 known drug resistance mechanisms in malignant cells and 1 known mechanism in TME cells are shown here.The "Signature" column represents the differentially expressed genes (DEGs) used for enrichment. The "Geneset" column represents the genes included in this mechanism. The "Overlap" column represents the number of genes in the "Geneset" that are enriched in the "Signature". The "Enriched Genes" column represents the genes in the "Geneset" that are enriched in the "Signature". (If the image exists, the user can click on it to enlarge it in a new window.)

Hallmark, KEGG and GOBP enrichment results for up-regulated genes in resistant group. Only show the top 50 pathways with fdr<0.05. If certain cell types are not displayed, it means that there are no significant pathways based on DEGs in those cell types. (If the image exists, the user can click on it to enlarge it in a new window. Complete files can be downloaded from the download section.)

Hallmark, KEGG and GOBP enrichment results for down-regulated genes in resistant group. Only show the top 50 pathways with fdr<0.05. If certain cell types are not displayed, it means that there are no significant pathways based on DEGs in those cell types. (If the image exists, the user can click on it to enlarge it in a new window. Complete files can be downloaded from the download section.)

Top

MicroRNAs (miRNAs) regulating drug resistance-related DEGs for malignant cells

In the pre-treatment samples, the miRNAs with a score greater than 80 that regulate the top10 abs(avg_log2FC) drug resistance-related DEGs for malignant cells are shown here. If the gene does not have any miRNAs with a score greater than 80, it will not be shown. Here only the names of miRNAs with a score greater than 90 are shown, but some names will not be shown because of too many overlaps. (Complete files containing all datasets and cell types can be downloaded from the download section.)

In the post-treatment samples, the miRNAs with a score greater than 80 that regulate the top10 abs(avg_log2FC) drug resistance-related DEGs for Malignant cells are shown here. If the gene does not have any miRNAs with a score greater than 80, it will not be shown. Here only the names of miRNAs with a score greater than 90 are shown, but some names will not be shown because of too many overlaps. (Complete files containing all datasets and cell types can be downloaded from the download section.)

Regulating up-regulated DEGs in resistant group	Regulating down-regulated DEGs in resistant group

This dataset only has one patient or is a cell line dataset, the resistant sample is the post-treatment sample and the sensitive sample is the pre-treatment sample. The miRNAs with a score greater than 80 that regulate the top10 abs(avg_log2FC) drug resistance-related DEGs for Malignant cells are shown here. Here only the names of miRNAs with a score greater than 80 are shown, but some names will not be shown because of too many overlaps. If the gene does not have any miRNAs with a score greater than 90, it will not be shown. (Complete files containing all datasets and cell types can be downloaded from the download section.)

Top

Motifs and transcription factors (TFs) regulating drug resistance-related DEGs for each cell type

In the pre-treatment samples, the motifs and TFs that regulate drug resistance-related DEGs for each cell type are shown here. (Complete files can be downloaded from the download section.)

In the post-treatment samples, the motifs and TFs that regulate drug resistance-related DEGs for each cell type are shown here. (Complete files can be downloaded from the download section.)

Motifs and TFs regulating up-regulated DEGs in resistant group of the post-treatment samples

motif	motif	NES	AUC	TF_highConf	Cell_type
	kznf__ZNF613_Imbeault2017_RP_RCADE	5.97	0.16	ZNF613 (directAnnotation).	B cells
	jaspar__MA1125.1	5.87	0.158	ZNF384 (directAnnotation).	B cells
	transfac_pro__M01250	5.02	0.138	E2F1 (directAnnotation).	B cells
	transfac_public__M00415	4.85	0.135	ZEB1 (directAnnotation).	B cells
	tfdimers__MD00187	4.58	0.129	GATA1; GATA2; GATA3; GATA4; GATA5; GATA6 (directAnnotation).	B cells
	transfac_pro__M06678	4.43	0.125	ZNF287 (inferredBy_Orthology).	B cells
	taipale_tf_pairs__ELK1_FOXI1_RSCGGAANRWMAACAN_CAP_repr	4.4	0.125	ELK1; FOXI1 (directAnnotation).	B cells
	metacluster_167.5	4.34	0.123	EHF; ELF5; NFATC3; SPI1; SPI1; SPI1; SPI1; SPI1; SPI1; SPI1; SPI1; SPI1; SPI1; SPI1; SPIB; SPIB; SPIB; SPIB; SPIB; SPIB; SPIB; SPIB; SPIB; SPIB; SPIC; SPIC; STAT5A (directAnnotation). ETS1; SPI1; SPI1; SPI1; SPI1; SPI1; SPI1; SPIB; SPIC (inferredBy_Orthology).	B cells
	metacluster_130.2	4.15	0.119	ZNF182; ZNF22; ZNF225; ZNF225; ZNF285; ZNF362; ZNF362; ZNF384; ZNF487; ZNF512; ZNF570; ZNF613 (directAnnotation). ZNF384 (inferredBy_Orthology).	B cells
	dbtfbs__GMEB1_K562_ENCSR928KOR_merged_N1	4.15	0.119	GMEB1 (directAnnotation).	B cells

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

Motifs and TFs regulating down-regulated DEGs in resistant group of the post-treatment samples

motif	motif	NES	AUC	TF_highConf	Cell_type
	metacluster_2.8	6.11	0.0846	IRF4; IRF5; IRF6; IRF9 (directAnnotation). IRF3; IRF5; IRF5; IRF6 (inferredBy_Orthology).	B cells
	metacluster_2.9	4.65	0.0704	IRF2; IRF2; IRF2; PRDM1; PRDM1 (directAnnotation). PRDM1 (inferredBy_Orthology).	B cells
	jaspar__MA1952.1	4.48	0.0688	FOXJ2 (directAnnotation).	B cells
	metacluster_2.6	4.02	0.0642	IRF1; IRF1; IRF1; IRF1; IRF1; IRF1; IRF1; IRF1; IRF1; IRF1; IRF2; IRF2; IRF2; IRF2; IRF2; IRF2; IRF2; IRF3; IRF3; IRF3; IRF3; IRF3; IRF3; IRF4; IRF4; IRF4; IRF4; IRF4; IRF5; IRF5; IRF5; IRF5; IRF5; IRF5; IRF5; IRF6; IRF7; IRF7; IRF7; IRF7; IRF7; IRF7; IRF7; IRF8; IRF8; IRF8; IRF8; IRF8; IRF8; IRF8; IRF8; IRF9; IRF9; IRF9; IRF9; IRF9; IRF9; IRF9; STAT1; STAT2; STAT2; STAT2; STAT2; ZNF426; ZNF71 (directAnnotation). IRF1; IRF1; IRF3; IRF8 (inferredBy_Orthology).	B cells
	metacluster_113.4	4.01	0.0642	MYB; MYB; MYBL1; MYBL2 (directAnnotation). MYB; MYB; MYBL1; MYBL2 (inferredBy_Orthology).	B cells
	jaspar__MA0776.1	3.95	0.0636	MYBL1 (directAnnotation).	B cells
	transfac_pro__M05803	3.75	0.0616	ZNF584 (directAnnotation).	B cells
	metacluster_22.21	3.6	0.0601	NFE2L2 (inferredBy_Orthology).	B cells
	tfdimers__MD00007	3.56	0.0598	E2F1; IRF8 (directAnnotation).	B cells
	tfdimers__MD00138	3.54	0.0595	IRF1; IRF2; IRF3; IRF4; IRF5; IRF7; IRF8; IRF9; MYB (directAnnotation).	B cells

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57

This dataset only has one patient or is a cell line dataset, the resistant sample is the post-treatment sample and the sensitive sample is the pre-treatment sample. Motifs and TFs that regulate drug resistance-related DEGs for each cell type are shown here. (Complete files can be downloaded from the download section.)

Top

Differentially expressed genes act as transcription factors

This table shows the differentially expressed genes that act as transcription factors. (Complete files can be downloaded from the download section.)

TF	motif	Expression	Cell type	Timepoint
IRF7	metacluster_2.6	down	B cells	post
STAT1	metacluster_2.6	down	B cells	post
STAT2	metacluster_2.6	down	B cells	post
IRF7	tfdimers__MD00138	down	B cells	post
IRF7	metacluster_2.7	down	B cells	post
STAT1	metacluster_2.7	down	B cells	post
STAT2	metacluster_2.7	down	B cells	post
SPIB	metacluster_167.5	down	B cells	post
STAT1	cisbp__M11350	down	B cells	post
STAT1	tfdimers__MD00177	down	B cells	post

Page: 1 2

1	"Sun X, Zhang Y, Li H, Zhou Y, Shi S, Chen Z, He X, Zhang H, Li F, Yin J, Mou M, Wang Y, Qiu Y, Zhu F. DRESIS: the first comprehensive landscape of drug resistance information. Nucleic Acids Res. 2023 Jan 6;51(D1):D1263-D1275. doi: 10.1093/nar/gkac812. PMID: 36243960; PMCID: PMC9825618."
2	"Wishart DS, Feunang YD, Guo AC, Lo EJ, Marcu A, Grant JR, Sajed T, Johnson D, Li C, Sayeeda Z, Assempour N, Iynkkaran I, Liu Y, Maciejewski A, Gale N, Wilson A, Chin L, Cummings R, Le D, Pon A, Knox C, Wilson M. DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018 Jan 4;46(D1):D1074-D1082. doi: 10.1093/nar/gkx1037. PMID: 29126136; PMCID: PMC5753335."